Osporil (Zoledronic Acid)

Zoledronic Acid is used in clinical practice to manage disorders that affect bone remodeling and calcium metabolism.

• Osteoporosis: reduces risk of vertebral and hip fractures in post‑menopausal women and men at high risk.
• Paget’s disease of bone: normalises bone turnover and alleviates bone pain.
• Bone metastases and hypercalcaemia of malignancy: lowers serum calcium and delays skeletal‑related events.

• Zoledronic Acid binds to hydroxy‑apatite crystals at sites of active bone resorption and is internalised by osteoclasts. Within the cell it inhibits farnesyl‑pyrophosphate synthase, a key enzyme of the mevalonate pathway, preventing prenylation of small GTP‑binding proteins and leading to osteoclast apoptosis, thereby reducing bone turnover.

Adverse reactions to zoledronic acid vary in frequency and severity.

Common Side Effects

• Acute‑phase flu‑like symptoms: fever, myalgia, arthralgia.
• Musculoskeletal pain: bone, joint or muscle discomfort.
• Nausea or vomiting.
• Transient elevation of serum creatinine.
• Headache.

Serious or Rare Side Effects

• Severe renal impairment or acute kidney injury.
• Osteonecrosis of the jaw (ONJ).
• Atypical femoral fractures.
• Hypocalcaemia.
• Severe hypersensitivity reactions, including anaphylaxis.

When using zoledronic acid, clinicians should consider several safety measures.

• Renal function assessment: evaluate baseline creatinine clearance before infusion.
• Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
• Dental health: perform oral examination and treat existing dental disease before therapy.
• Concomitant nephrotoxic drugs: avoid or monitor use of NSAIDs, aminoglycosides, or contrast agents.
• Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Zoledronic acid may interact with several co‑administered agents, requiring vigilance.

Major Interactions (Avoid)

• Nephrotoxic agents such as high‑dose NSAIDs, aminoglycosides and iodinated contrast media.
• Concomitant use of bisphlycer   ---

Moderate Interactions (Monitor Closely)

• Calcium‑containing antacids or supplements taken within 4 h of the infusion.\n- Loop‑diuretics (e.g., furosemide) that may affect calcium balance.
• Vitamin D analogues (calcitriol) that alter calcium metabolism.
• Oral bisphosphonates administered concurrently.